Eric Lefkofsky Keeps on Giving

Eric Lefkofsky lives a life that is driven by his passion to build innovative businesses and his desire to give back to others. Eric Lefkofsky was born in 1969 in Detroit Michigan. He is married to Elizabeth Lefkofsky, and he graduated from the University of Michigan Law school in 1993. Besides being in extremely generous entrepreneur, Eric Lefkofsky has innovated companies that have soared in their markets.

Tempus is a company that deals with brilliant healthcare technology. This technology enables physicians to give their patient’s state of the art cancer treatments. Since each individual has a body that is unique, it stands to reason that their cancer treatment should be just as remarkable. Tempus provides genetic services that analyze human cells on a molecular level. The data that is obtained from these test allow physicians to make decisions about their patient’s cancer treatment. This is an innovative way to help patients get targeted treatment for their specific cancer; in that way, they better care.

Groupon is a very well-known internet sales company that was spearheaded by Eric Lefkofsky. Groupon is known as the worldwide leader of online commerce. Groupon allows individuals to buy just about anything they would like through their website. Groupon has built several relationships with retailers and businesses all around the world, and they leverage those relationships in order to give their clients the best deals on services, products, and travel. Groupon also gives their customers occasional rebates on their already low prices as well and learn more about Eric.

Apart from starting multiple world changing companies, Eric Lefkofsky and his wife Elizabeth started The Lefkofsky Foundation. This is a foundation that gives to a large array of charities around the world. Their Foundation has a focus on the arts and education. Eric Lefkofsky and his wife have donated millions of dollars through their charity, and they continue with their giving endeavours. Eric Lefkofsky is in a class of his own when it comes to innovation and philanthropy and more information click here.

The CEO Behind the Technology to Treat Breast Cancer

Breast cancer is one of the most harmful types of cancer that have already targeted hundreds of individuals in the U.S., mostly women, but men are not free from it. Because it is so typical, it is common sense that researchers would have much more extensive data on the disease than they actually have and read full article.

The main reason because there isn’t that much extensive information that detects patterns among current individuals with breast cancer and past ones is that scientists lack a functional system that is able to store this type of data.

However, recent news are going to change this reality forever as Eric Lefkofsky announced that his project, Tempus, is ready to be used in laboratories to assist in developing new therapies and methods to treat cancer based on past infected patients.

But, how do they do that?

First, we have to understand Tempus as a massive search engine, like Google but specialized in searching specific information about patients.

While treating a patient with breast cancer, now physicians could use Tempus to detect patterns in previous hosts that have similar characteristics and understand more about what to expect from the advancement of the disease and what therapies worked while what were the ones that didn’t.

Eric Lefkofsky is the founder of many successful startups like Groupon and has dedicated his newest investments in developing the technology Tempus, which is based in Chicago.

The first and currently the only scientists that will use Tempus to treat breast cancer are the doctors of the University of Chicago. Eric made a partnership with the University and will be lending the software that will improve their efficiency while the University will produce the best professionals to treat the disease and learn more about Eric.

The positive results of the system might take a while to show up, but it will be a step forward in developing more intelligent ways to combat diseases in the future, said a doctor of Chicago University.

  1. OlufunmilayoOlopade, the professor of medicine and human genetics at the same university, stated that, although breast cancer is among the most common cases of cancer, the thousands of patients that have been diagnosed with the disease have information that is very hard to access and understand with a full picture without dedicated software to do so.

The CEO of Tempus, Eric Lefkofsky, has done tons of advancements for the world of medicine, but this investment in the area is something new to the entrepreneur. He was a former owner of a venture fund named Lightbank and co-founder of Uptake Technologies.

Even if Lefkofsky does not have knowledge in the area of medicine, he has tons of experience in developing technologies that offer solutions and Eric’s lacrosse camp.

Oncotarget is One of the Top Scholarly Journals with Millions of Citations

Oncotarget is a peer-reviewed journal famous for its constructive, punctual, insightful, and multiple reviews that assist scientists to sensitize and increase the impact of research. This journal was launched by Dr. Mikhail Blagosklonny of the Roswell Park Cancer Institute together with his colleague Andrei V. Gudkov. Dr. Blagosklonny and Mr. Gudkov are the editors of this journal. These two scholars established this journal with the objective of:

  • Making scientific results readily available on a weekly basis.
  • Enhance the impact of research.
  • Share discoveries promptly.
  • Merge different fields of medicine.
  • Encourages the use of clinical and basic science to fight against diseases.

Oncotarget is managed by some of the prominent scientists in the field of oncology who help contribute to the progress of research. This journal has gained popularity in the last seven years, and this has prompted it to launch some sections beyond cancer research. These topics include cell biology, neuroscience, endocrinology, cardiology, pharmacology, and metabolism. Oncotarget publishes four main types of articles including editorial & news, reviews, research papers, and books. Read more about Oncotarget at Bioxbio.

Editorials are mainly discussions by authors about their already published articles in other journals. Onctotaget publishes these articles with conditions that they must have a word limit of 800 words and less than seven references. This journal also publishes reviews mostly about broadly discussed topics. Reviews should contain figures and at least ninety references. Research papers, on the other hand, should have no word or text limit. Oncotarget recommends that books to be published should have colored figures with a minimal number of five hundred references.

Oncotarget’s leadership

Among the chief editors of this journal is Dr. Blagosklonny who equips students at the Roswell Park Cancer Institute with oncological knowledge. He has published over 260 articles and, hence, experienced and skilled when it comes to editing research papers. His efforts have made Oncotarget be recognized as one of the most prominent journals in the United States. Mr. Gudkov is the senior VP of basic research at the Roswell Park Cancer Institute. He is an expert in molecular biology and experimental oncology. Mr. Gudkov has vested interest in gene & drug discovery and molecular targets for cancer treatment. Oncotarget is also available on Dove Press.